Arkema has chosen the location of Jurong Island in Singapore to build its new world-scale plant dedicated to the manufacture of the amino 11 monomer and its flagship Rilsan® polyamide 11 resins. With this 50% increase in its global capacities announced in July 2017, the Group supports strong demand from its customers in Asia for high-performance bio-sourced solutions addressing the major opportunity of material lightweighting in particular.
 |
Arkema has chosen the Jurong Island site in Singapore to set up its new bio-sourced polyamide production site. This location offers many advantages in terms of infrastructure, logistics, industrial integration and operational excellence, as well as optimization of the activity’s carbon footprint.
Rilsan® polyamide 11 is derived from castor oil and so is the only 100% bio-sourced polyamide approved for many of the most demanding applications, in particular in the electronics, 3D printing, oil and gas extraction, and automotive markets, as a substitute to metal.
This project is part of the Group’s exceptional investments totaling some 500 million euros earmarked for the 2018-2021 period essentially. Construction is scheduled to be completed by late 2021.
|
"This major investment bolsters our global presence in bio-sourced materials while bringing us significantly closer to our customers in Asia. Singapore’s industrial and innovation-friendly environment is, we believe, a key asset for our project." |
